Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting
Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting From Highly Emetogenic Chemotherapy: a Randomized, Multicenter, Double-blind, Placebo-controlled Phase III Trial
Sponsor: Anshan Tumor Hospital
Listed as NCT02203253, this PHASE3 trial focuses on Neoplasms and remains completed. Sponsored by Anshan Tumor Hospital, it has been updated 6 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Jan 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Jan 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anshan Tumor Hospital
- China Medical University, China
- General Hospital of Shenyang Military Region
- Liaoning Cancer Hospital & Institute
- Liaoyang Central Hospital
- Petrochemical General Hospital of Liaoyang city
- Shengjing Hospital
- The First Affiliated Hospital of Dalian Medical University
- The First Hospital of Liaoning Medical University
- The Second Affiliated Hospital of Dalian Medical University
- Third People's hospital Liaoyang
For direct contact, visit the study record on ClinicalTrials.gov .